Publications scientifiques
Nafissatou Maboune
David Goda
Dany Joël Ngassa Ngoumen
Jules Kamga Nanhah
Bruno Dupon Akamba Ambamba
Maxwell Wandji Nguedjo
Fils Armand Ella
Guy Roussel Takuissu Nguemto
Judith Laure Ngondi* (Auteur correspondant)
Jean Paul Chedjou
Javeres Leonel Ntepe Mbah
American Journal of Biomedical and Life Sciences
DNA methylation is an epigenetic mechanism involved in the regulation of blood lipid levels which contribute to the cardiovascular risk in diabetic patients. Active agents that target atherogenic dyslipidemias epigenetically are therefore of paramount interest for prevention of cardiovascular complications in these patients. This study aims at evaluating the antiatherogenic effect of hydroethanolic extract<i> </i>of <i>A. congolensis</i> (HEEAC) on diabetic rats. Diabetes was induced by a single dose of 50 mg/kg b.w streptozotocin. Diabetic rats were then treated with 150 mg/kg b.w of HEEAC or with atorvastatin 10 mg/kg b.w (reference drug) for 28 days. At the end of the experimental period, rats were sacrificed, blood samples and liver tissues were collected and the plasma concentrations of triglycerides (TG), total cholesterol (TC), HDL-cholesterol and LDL-cholesterol were assessed. The atherogenic indices were also calculated and the liver and blood DNA extracted to determine DNA methylation. Comparing to untreated diabetic rats, the HEEAC treated group showed significant lower values of TG 245.98 ± 41.39 vs 57.88 ± 10.64 mg/dL (p < 0.05), TC 159.88 ± 17.56 vs. 87.77 ± 9.51 mg/dL (p < 0.05), LDL-C 94.51 ± 0.66 vs 48.71 ± 1.45 mg/dL (p < 0.05) and higher values of HDL-C 19.55 ± 1.6 vs 27.49 ± 1.45 (p < 0.05). Atherogenic indices were significantly lowered in HEEAC-group. The effects of HEEAC on lipid profile and atherogenic indices were significantly higher than atorvastatin. Also, the percentage of global hepatic DNA methylation (0.34±0.033 vs 0.63±0.023 %) was significantly increased in HEEAC-group compared to untreated diabetic group. DNA methylation profile in HEEAC-group correlated negatively and significantly (P < 0.01) with LDL-C and TC levels. HEEAC prevents atherogenic dyslipidemia in diabetic rats by targeting global DNA-methylation status in diabetic rats.
